Table 3 Summary of multivariable analyses of prognostic factors.
HR (95% CI) | p value | |
|---|---|---|
Overall survival | ||
treament group | 1.422 (0.506–4.001) | 0.504 |
Gender | 4.017 (0.508–31.779) | 0.188 |
Age (<50 vs >50) | 2.083 (0.808–5.369) | 0.129 |
T3 vs T1–2 | 1.343 (0.385–4.680) | 0.643 |
T4 vs T1–2 | 0.688 (0.135–3.520) | 0.654 |
N1 vs N3 | 0.368 (0.052–2.590) | 0.316 |
N2 vs N3 | 0.337 (0.070–1.624) | 0.175 |
grade | 1.454 (0.248–8.528) | 0.678 |
Rash | 2.916 (1.388–6.125) | 0.005 |
Progression-free survival | ||
treament group | 1.248 (0.526–2.963) | 0.615 |
Gender | 1.189 (0.385–3.668) | 0.764 |
Age (<50 vs >50) | 1.601 (0.727–3.526) | 0.243 |
T3 vs T1–2 | 0.694 (0.220–2.196) | 0.535 |
T4 vs T1–2 | 1.406 (0.333–5.930) | 0.643 |
N1 vs N3 | 0.301 (0.064–1.423) | 0.130 |
N2 vs N3 | 0.258 (0.069–0.962) | 0.044 |
grade | 2.047 (0.396–10.595) | 0.393 |
Rash | 2.526 (1.407–4.537) | 0.002 |
Local recurrence-free survival | ||
treament group | 0.326 (0.075–1.418) | 0.135 |
Gender | 0.591 (0.105–3.319) | 0.550 |
Age (<50 vs >50) | 1.075 (0.249–4.642) | 0.923 |
T3 vs T1–2 | 1.806 (0.277–11.780) | 0.537 |
T4 vs T1–2 | 0.562 (0.048–6.518) | 0.645 |
N1 vs N3 | 1.975 (0.148–26.302) | 0.606 |
N2 vs N3 | 0.582 (0.070–4.848) | 0.617 |
grade | 0.491 (0.047–5.086) | 0.551 |
Rash | 3.641 (1.365–9.714) | 0.010 |
Distant metastasis free survival | ||
treament group | 2.248 (0.735–6.875) | 0.156 |
Gender | 1.487 (0.315–7.012) | 0.616 |
Age (<50 vs >50) | 1.836 (0.710–4.752) | 0.210 |
T3 vs T1–2 | 0.343 (0.067–1.757) | 0.199 |
T4 vs T1–2 | 2.204 (0.366–13.258) | 0.388 |
N1 vs N3 | 0.119 (0.015–0.934) | 0.043 |
N2 vs N3 | 0.175 (0.033–0.928) | 0.041 |
grade | 4.530 (0.505–40.667) | 0.177 |
Rash | 2.307 (1.141–4.664) | 0.020 |
